Novo Nordisk Launches Wegovy in China

Novo Nordisk's obesity drug Wegovy goes on sale in China
Novo Nordisk's blockbuster weight-loss drug Wegovy is now available for use in China, the company confirmed to AFP on Tuesday, as the Asian nation battles high rates of obesity.A Novo Nordisk spokesperson confirmed to AFP on Tuesday that the drug was "now available in China" for the treatment of adults with obesity and those overweight with at least one weight-related comorbidity.
Novo Nordisk Launches Wegovy in China With Prices Below US
Novo Nordisk A/S is launching its top-selling Wegovy obesity drug in China at a fraction of the US price, a key step in unlocking a big, fast-growing market for its blockbuster franchise.
Novo Nordisk has launched obesity drug Wegovy in China
Novo Nordisk said on Monday it has launched its popular obesity drug Wegovy in China, the world's second-largest pharmaceuticals market. A spokesperson for the Danish drugmaker confirmed the news to Reuters after it was first reported by financial media outlet Yicai.
Popular weight-loss drug Wegovy goes on sale in China
Novo Nordisk has launched its weight-loss drug Wegovy in China after it was approved by local health authorities in June. It is set to intensify competition with rival Eli Lilly, whose popular weight-loss treatment also got the green light months ago but has yet to go on sale in the world's second largest pharmaceutical market.
Weight-loss drug Wegovy launched in China
Novo Nordisk said Monday it has launched its popular obesity drug Wegovy in China, the world’s second-largest pharmaceuticals market where it estimates more than 180 million people live with obesity.
Weight-Loss Drug Wegovy comes to China Amid Rising Demand
Novo Nordisk has officially launched its weight-loss drug Wegovy in China after receiving approval in June. The move pits it against rival Eli Lilly, whose treatment, Zepbound, is yet to hit shelves in the world's second-largest pharmaceutical market.
Novo Nordisk reportedly launches Wegovy in China
Novo Nordisk (NVO) has reportedly launched its popular weight-loss drug Wegovy in China ahead of a rival drug by Eli Lilly (LLY). Read more here.
Novo Nordisk launches obesity drug Wegovy in China
Novo Nordisk said on Monday it has launched its popular obesity drug Wegovy in China, the world's second-largest ...
Business Insider1d
Novo Nordisk’s Ambitious Share Buyback Initiative
Novo Nordisk (NVO) has released an update. Don't Miss our Black Friday Offers: Novo Nordisk has launched a share repurchase program, aiming to buy back B shares worth up to DKK 20 billion over ...
Benzinga.com1d
Novo Nordisk To Offer Wegovy In China At Fraction Of USA Cost
Novo Nordisk's Wegovy launch in China begins in Shanghai at $194 per four-injection pack, significantly cheaper than U.S.
Novo Nordisk says it is gradually phasing out human insulin pens globally
Novo Nordisk is gradually ending production of human insulin pens, the drugmaker told Reuters, as it spends billions to ramp ...
Novo Nordisk Insulin Plans Spark Angst Among Diabetes Patients
About 400 people marched to the South African headquarters of Novo Nordisk A/S in Johannesburg this week demanding greater ...
Yahoo6d
Here's Why Novo Nordisk (NVO) is a Strong Growth Stock
Bagsværd, Denmark-based Novo Nordisk is a global healthcare company and a leader in the worldwide diabetes market with a ...
EU regulators quiz Novo Nordisk, Catalent rivals on $16.5 bln deal
EU antitrust regulators have asked pharma rivals and customers for feedback in four business areas in light of Novo Holdings' ...
Investopedia on MSN12d
Novo Nordisk Stock Slips as Sales Grow Less Than Expected
After rising in premarket trading, Novo Nordisk's U.S.-listed shares fell after the market opened Wednesday as its ...
Medicaid dominates coverage of Novo, Lilly weight-loss drugs
State Medicaid programs for low-income families are the single biggest source of coverage, giving 31.6 million people access ...